

Japan's Eisai inaugurates new headquarters in US

19 August 2022 | News

State-of-the-art Eisai US *hhceco* Center underscores New Jersey as the premier life science hub

Eisai Inc., the US pharmaceutical subsidiary of Japanese firm Eisai Co, has announced the grand opening of its new headquarters, the Eisai US *hhceco* Center, in Nutley, New Jersey. This new facility, on the ON3 Campus, is strategically located to advance the company's *human health* care (*hhc*) mission, which has a strong structure of collaborative relationships that further its work to address the needs of people throughout their lives.

The Eisai US *hhceco* Center will expand the diverse and powerful life sciences community in New Jersey, bringing a dedicated commitment to addressing pressing medical challenges in cancer, Alzheimer's disease and other neurological diseases.

Eisai's Global CEO, Haruo Naito, highlighted how the company is expanding its longstanding *hhc* mission to address healthcare's most pressing challenges, based on the concept of an ecosystem model in which organizations share technologies, exchange values and grow together to deliver health-related solutions that matter to people and contribute to society – called *hhceco*.

With preeminent neighbors that provide healthcare and educate the next generation of clinical specialists, Eisai's US *hhceco* Center is ideally located to foster existing collaborations and develop important new relationships. Additionally, the building offers a dynamic, technologically advanced environment that further enables the company's commitment to innovation. The new 332,800 square foot facility brings approximately 800 jobs to the Nutley-Clifton area and, at full capacity, will

accommodate 1,300 employees.